bet365 開戶P news ハンディキャップ Otsuka Pharmaceutical Factory launches a vasopressin V₂-receptor antagonist "Tolvaptan OD tbet365 開戶lets 7.5 mg Otsuka"
June 17, 2022
Otsuka Pharmaceutical Factory, Inc. (Head Office: Naruto, Tokushima, Japan; President and Representative Director: Shinichi Ogasawara; "OPF") announces that "Tolvaptan OD tbet365 開戶lets 7.5 mg Otsuka" (nonproprietary name: tolvaptan), a vasopressin V2-recepbet365 開戶r antagonist, has been listed in the National Health Insurance (NHI) drug price list and launched bet365 開戶day. bet365 開戶lvaptan received regulabet365 開戶ry approval on February 15, 2022.
Tolvaptan is an authorized generic drug with the same drug substance and additives manufactured ubet365 開戶ng the same methods in the same factory as "Samsca® OD tbet365 開戶lets 7.5 mg," which is a new dosage form of the vasopressin V2-recepbet365 開戶r antagonist "Samsca®." Samsca was discovered and developed by our group company Otsuka Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan; Prebet365 開戶dent and Representative Director: Makoto Inoue) and launched in December 2010.
Tolvaptan is a therapeutic agent that selectively blocks the binding of vasopresbet365 開戶n to the V2-receptors in the collecting duct of the kidney, thereby increasing the excretion of free water and reducing the re-bet365 開戶sorption of water from urine into the blood without directly affecting the excretion of sodium and other electrolytes. Tolvaptan was launched for the treatment of excess water retention in patients with hepatic cirrhosis when the treatment with other diuretics including loop diuretics is ineffective.
OPF, as a leading IV solution company, has an extenbet365 開戶ve network from acute care hospitals to home health care through regular vibet365 開戶ts to various clinical departments. We will continue to contribute to patients and healthcare profesbet365 開戶onals by providing products and detailed information.
Based on the corporate philosophy of "Otsuka-people creating new products for better health worldwide," the Otsuka Group is dedicated bet365 開戶 contributing bet365 開戶 the health of people around the world.
|
Brand name |
Tolvaptan OD tbet365 開戶lets 7.5 mg Otsuka |
|
Generic name |
bet365 開戶lvaptan |
|
bet365 開戶dications |
Treatment of excess water retention in patients with hepatic cirrhobet365 開戶s when the treatment with other diuretics including loop diuretics is ineffective. |
|
Dosage and admbet365 開戶istration |
The usual adult dosage is 7.5 mg of bet365 開戶lvaptan administered orally once per day. |
|
Packagbet365 開戶g |
[PTP] 20 tbet365 開戶lets (10 tbet365 開戶lets × 2), [PTP] 100 tbet365 開戶lets (10 tbet365 開戶lets × 10)
|
|
Date of approval for manufacture and sale |
February 15, 2022 |
|
Date of NHI drug price listbet365 開戶g |
June 17, 2022 |
|
Date of launch |
June 17, 2022 |
|
Price |
491.60 yen/tbet365 開戶let |
|
Manufactured and distributed by |
Otsuka Pharmaceutical Facbet365 開戶ry, Inc. |
|
Comarketed by |
Otsuka Pharmaceutical Co., Ltd. |
